# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Eroxon® is Haleon's first offering in the sexual health space Clinical studies show Eroxon® is safe and effective in men wi...
Updating guidance for FY2024 and confident of delivery on medium term guidance ● Organic revenue growth expected to be 4-6% ● ...
Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories SA for £50...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol an...
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners.
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advi...